Tudor Investment Corp ET AL Purchases Shares of 154,999 ProAssurance Co. (NYSE:PRA)

Tudor Investment Corp ET AL acquired a new position in shares of ProAssurance Co. (NYSE:PRA) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 154,999 shares of the insurance provider’s stock, valued at approximately $2,466,000. Tudor Investment Corp ET AL owned 0.30% of ProAssurance as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also made changes to their positions in the stock. Wealthfront Advisers LLC acquired a new position in shares of ProAssurance in the 4th quarter valued at $359,000. Amundi lifted its stake in ProAssurance by 182.3% during the fourth quarter. Amundi now owns 25,634 shares of the insurance provider’s stock worth $389,000 after purchasing an additional 16,552 shares during the period. Prudential Financial Inc. boosted its holdings in ProAssurance by 57.3% during the fourth quarter. Prudential Financial Inc. now owns 86,703 shares of the insurance provider’s stock valued at $1,379,000 after purchasing an additional 31,580 shares in the last quarter. American Century Companies Inc. grew its stake in shares of ProAssurance by 17.2% in the 4th quarter. American Century Companies Inc. now owns 391,609 shares of the insurance provider’s stock valued at $6,230,000 after purchasing an additional 57,556 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in shares of ProAssurance by 28.0% during the 4th quarter. JPMorgan Chase & Co. now owns 323,955 shares of the insurance provider’s stock worth $5,154,000 after buying an additional 70,780 shares during the period. Institutional investors and hedge funds own 85.58% of the company’s stock.

ProAssurance Price Performance

PRA opened at $23.01 on Friday. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.28 and a quick ratio of 0.28. The stock has a market capitalization of $1.18 billion, a P/E ratio of 27.72 and a beta of -0.09. The company’s 50 day simple moving average is $20.74 and its 200-day simple moving average is $17.41. ProAssurance Co. has a one year low of $10.76 and a one year high of $23.70.

ProAssurance (NYSE:PRA) last released its earnings results on Monday, February 24th. The insurance provider reported $0.36 EPS for the quarter, beating the consensus estimate of $0.17 by $0.19. The company had revenue of $287.52 million during the quarter, compared to analysts’ expectations of $274.56 million. ProAssurance had a return on equity of 2.65% and a net margin of 3.71%. Sell-side analysts anticipate that ProAssurance Co. will post 0.8 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

PRA has been the subject of several recent analyst reports. StockNews.com assumed coverage on ProAssurance in a research note on Saturday. They set a “hold” rating for the company. Citigroup cut shares of ProAssurance to a “market perform” rating in a research note on Thursday, April 3rd. Citizens Jmp downgraded ProAssurance from an “outperform” rating to a “market perform” rating in a report on Thursday, April 3rd. Finally, Raymond James lowered ProAssurance from a “market perform” rating to an “underperform” rating in a research report on Thursday, April 10th. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $18.67.

ProAssurance Company Profile

ProAssurance Corporation, through its subsidiaries, provides property and casualty insurance, and reinsurance products in the United States. The company operates through Specialty Property and Casualty, Workers’ Compensation Insurance, and Segregated Portfolio Cell Reinsurance segments. It offers professional liability insurance to healthcare providers and institutions, and attorneys and their firms; medical technology liability insurance to medical technology and life sciences companies; and custom alternative risk solutions, including assumed reinsurance, loss portfolio transfers, and captive cell programs for healthcare professional liability insureds.